New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
185680 ETF · Samsung KODEX SYNTH-US Biotech ETF
The 185680 Exchange Traded Fund (ETF) is provided by Samsung Asset Management. It is built to track an index: S&P Biotechnology Select Industry Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). This share class generates a stream of income by distributing dividends.
Last update 3/13/2026, 12:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.-3.64%
Last price
â‚©39,205
1M perf.
+2.81%
1M flows
-€583K
AuM
€12M
E/R
0.25%
Rating
Not rated
ESG Consensus®
185680
â‚©39,205
Performance & flows
Segment for quartile rank
December 11, 2025 → March 11, 2026
Create a free account to view the flows graph
185680
â‚©40,105.5
+4.03%
US Health Care
+0.23%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +2.81%  | +4.03% | +47.49% | +87.75% | +14.60%  | +1.61% | +4.60% | +4.60% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
Issuer
ISIN
KR7185680006
AuM
€12M
E/R
0.25%
Replication rating
Not rated
ESG Consensus®
More details
NAV
3/11/2026
â‚©40,105.5
1D NAV change
+0.12%
Dividend policy
Replication method
Indirect
Replication model
No. of holdings
149
Inception date
10/30/2013
Jurisdiction
South Korea
Distribution
South Korea
Legal structure
Open-end Investment Trust
Base currency
KRW
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
Samsung KODEX SYNTH-US Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +4.03% | +47.49% | +87.75% | +14.60% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Exposure based on a proxy
More info
Countries
USA
94.51%
Ireland
1.60%
Bermuda
1.30%
Switzerland
1.06%
Other
1.51%
Sectors
Health Care
88.03%
Unavailable
11.87%
Other
0.11%
Diversification
Exposure based on a proxy
More info
Total weight of top 15 holdings out of 149
Top 15 holdings
Data as of January 31, 2026
Exposure based on a proxy
More info
MODERNA INC
MIRUM PHARMACEUTICALS INC
REVOLUTION MEDICINES INC
VAXCYTE
AMICUS THERAPEUTICS
US74006W2070
ALKERMES
GILEAD SCIENCES
Create a free account to view top holdings
KRYSTAL BIOTECH INC
HALOZYME THERAPEUTICS
AMGEN-T
CELCUITY INC
ROIVANT SCIENCES LTD
BRIDGEBIO PHARMA
VERTEX PHARMACEUTICALS
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Samsung Asset Management
Samsung Asset Management ID Card
Number of funds
145
Total AuM
€58.24B
Expense ratio range
0.015% - 2.28%
Average expense ratio
0.3679%
Top 5 funds by Samsung Asset Management
| AuM | ||
|---|---|---|
069500 | Samsung KODEX 200 ETF | €10.53B |
379800 | KODEX S&P500 TR | €4.76B |
459580 | Samsung Kodex CD Rate Active(SYNTH) ETF | €4.74B |
229200 | Samsung KODEX KOSDAQ 150 ETF | €4.29B |
278530 | Samsung KODEX 200 Total Return ETF | €3.33B |
Frequently asked questions about 185680
What does Samsung KODEX SYNTH-US Biotech ETF, 185680, invest in?
185680 is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.
Which benchmark or index does 185680 replicate?
185680 tracks the S&P Biotechnology Select Industry Index - USD, through a replication method.
What is the Total Expense ratio (TER) of 185680?
185680 carries a total expense ratio (TER) of 0.25%, indicating the annual cost for holding the fund.
When was 185680 launched?
185680 was introduced to the market on October 30, 2013. It trades on South Korea
Who is the ETF issuer of 185680?
Samsung KODEX SYNTH-US Biotech ETF, 185680, is provided by Samsung Asset Management. Learn more about Samsung Asset Management here.
What is the current assets under management (AUM) of 185680?
185680 oversees €12M in assets as of March 11, 2026.
How has 185680 performed lately?
Based on data from March 11, 2026, 185680 returned 2.81% over the past month, 4.03% over the last three months and 4.60% year-to-date.
What are the latest inflows or outflows for 185680?
As of March 11, 2026, 185680 recorded net flows of -€586K over the last month and -€518K year-to-date.
Does 185680 distribute dividends?
185680 follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of 185680?
As of January 31, 2026, 185680 has significant geographic allocations in USA, Ireland and Bermuda.
In which sector or theme does 185680 invest in?
As of January 31, 2026, 185680 focuses largely on Health Care.
How many securities does 185680 hold and how diversified is it?
As of January 31, 2026, 185680 holds 149 positions in its portfolio, with 21.60% of assets concentrated in its top 15 holdings.
What are the main positions in 185680?
As of January 31, 2026, 185680 top three holdings include MODERNA INC, MIRUM PHARMACEUTICALS INC and REVOLUTION MEDICINES INC.
What is the base currency of 185680?
The base currency of 185680 is KRW.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
